Novartis saw a treatment for a rare muscle-wasting disease fail a late-stage study, the third clinical-trial setback in a week. The medicine was the centerpiece of Novartis’s $12 billion takeover of Avidity Biosciences and raises questions about the drugmaker’s growth prospects. Fabienne Kinzelmann reports on Bloomberg Television. (Source: Bloomberg)
Novartis saw a treatment for a rare muscle-wasting disease fail a late-stage study, the third clinical-trial setback in a week. The medicine was the centerpiece of Novartis’s $12 billion takeover of Avidity Biosciences and raises questions about the drugmaker’s growth prospects. Fabienne Kinzelmann reports on Bloomberg Television. (Source: Bloomberg)
<iframe src="https://statesidedaily.com/embed/cluster/db073b7eb430bb260093c34907becd7bc5a95f59" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Novartis Sees Avidity Drug Suffer Third Clinical-Trial Setback"></iframe>
